105544-30-7

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-3-nitro-pyridin-2-yloxy)-acetic acid ethyl ester is used as a chemical intermediate for the synthesis of various organic compounds. Its unique chemical structure, including the pyridine ring with bromine and nitro groups, as well as the acetic acid ester, makes it a valuable reagent in the development of new pharmaceuticals and drug discovery processes.
Used in Organic Synthesis:
In the field of organic synthesis, 5-Bromo-3-nitro-pyridin-2-yloxy)-acetic acid ethyl ester is employed as a reagent due to its functional groups, which allow for various chemical reactions and the formation of new compounds. Its versatility in organic synthesis contributes to the development of novel chemical entities and materials.
Safety Considerations:
It is important to handle 5-Bromo-3-nitro-pyridin-2-yloxy)-acetic acid ethyl ester with proper safety measures, as it can be hazardous if not managed according to safety guidelines. Proper handling, storage, and disposal are essential to minimize risks associated with this chemical compound.

InChI:InChI=1/C9H9BrN2O5/c1-2-16-8(13)5-17-9-7(12(14)15)3-6(10)4-11-9/h3-4H,2,5H2,1H3

Upstream product

• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 38233-96-4 ethyl 2-hydroxyacetate sodium salt 
• 623-50-7 ethyl 2-hydroxyacetate 

Downstream Products

• 105544-36-3 7-bromo-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one 
• 107113-02-0 7-Bromo-3-[1-phenyl-meth-(Z)-ylidene]-1H-pyrido[2,3-b][1,4]oxazin-2-one 
• 1313441-32-5 ethyl 2-((3-nitro-5-phenylpyridin-2-yl)oxy)acetate 
• 1198154-03-8 7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one 
• 1313441-33-6 6-bromo-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one 
• 1313441-54-1 6-bromo-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-thione 
• 1313441-55-2 7-bromo-1-(difluoromethyl)-8-phenyl-4H-pyrido[2,3-b][1,2,4]triazolo[4,3-d][1,4]oxazine 
• 1313441-64-3 tert-butyl 4-(2-oxo-7-phenyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-6-yl)benzylcarbamate 
• 1313441-65-4 tert-butyl 4-(1-(cyanomethyl)-2-oxo-7-phenyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-6-yl)benzylcarbamate 
• 1313485-80-1 (E)-6-bromo-2-hydrazono-7-phenyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine 
• 1313441-66-5 7-bromo-1-ethyl-8-phenyl-4H-pyrido[2,3-b][1,2,4]triazolo[4,3-d][1,4]oxazine 
• 946121-78-4 7-bromo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine 

Relevant academic research and scientific papers

CHROMENOPYRIMIDINE DERIVATIVES AS PHOSPHATIDYLINSITOL PHOSPHATE KINASE INHIBITORS

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A1, A2, G, R1, R2, R3, R4, and W are described herein.

AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described herein.

HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosis. Formula (I) is shown below:

Short and efficient synthesis of oxazinone-and thiazinone-containing bicyclic heteroaromatic aldehydes

Short and efficient route for the synthesis of oxazinone-and thiazinone-containing bicyclic heteroaromatic aldehydes, which involves the key step of palladium-catalyzed reductive carbonylation, is described. Overall routes for the synthesis of these aldehydes are short, versatile, and scalable with good yields of the product. [Supplementary materials are available for this article. Go to the publisher's online edition of Synthetic Communications for the following free supplemental resource(s): Full experimental and spectral details.]

INHIBITORS OF AKT ACTIVITY

The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.

Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors

The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

FUSED HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof, or a salt thereof; and an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like.